Evolut Low-Risk Trial: 5-year Data Outcomes

Is the evidence convincing that intensive antihypertensive therapy protects brain function and helps prevent dementia? Research increasingly shows that high mid‑life blood pressure is a strong predictor of later cognitive decline. Emerging data further indicate that intensive blo ...  Show more

In patients with Type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), tirzepatide was non‑inferior to dulaglutide for major cardiovascular events while providing superior kidney protection, lower all‑cause mortality, and greater reductions in HbA1c and ...  Show more

Join our hosts Can Gollmann-Tepeköylü and Miia L Lehtinen for their late-breaking trials highlights presented at the 37th EACTS Annual Meeting in Vienna, including: 

<div>Today, we’re diving into a condition that’s as fascinating as it is complex: Achalasia—where the esophagus stops playing nice, and swallowing becomes a daily challenge.

We’re breaking down the latest evidence, comparing POEM ...  Show more

Join CardioNerds EP Council Chair Dr. Naima Maqsood and Episode Lead Dr. Jeanne De Lavallaz as they discuss the results of the ARREST-AF Trial with expert faculty Dr. Prashanthan Sanders and Dr. Mehak Dhande. Audio editing by CardioNerds intern Bhavya Shah. The ARREST-AF trial en ...  Show more

Artificial Intelligence (AI) already powers search results and chat bots, but what if it could help physicians diagnose cancer? In this episode of the BackTable ENT podcast, laryngologist Dr. Anthony Law of Emory University discusses applications of AI to laryngology with host Dr ...  Show more